AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02976675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
Study NCT02976675 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEG-somatropin
Description: Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
Study NCT02976675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
Study NCT02076737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model-based iterative reconstruction (MB-IR VEOTM) on CT Discovery 750HD (GE Healthcare, Milwaukee, WI)
Study NCT02614222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Blocks with CAIG
Description: The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
Study NCT04558606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonic Toothbrush
Description: Sonic Toothbrush (Philips Sonicare Flexcare Platinum Toothbrush®)
Study NCT04558606 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: Manual brushing (Technique Pro - GUM® Sunstar Italiana SRL)
Study NCT02793401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hıgh İntensity Laser (HILT)
Description: HILT was performed using a BTL-6000 High Intensity Laser, 12 W(watt), 1064 nm device was a hot laser with Nd: YAG LASER source. In HILT group, the investigators applied the device on the shoulder area in two phases: phase I - analgesia, and phase II - biostimulation.
Study NCT02793401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: BTL 4710 US device was applied at 3 MHz frequency, and 1.5watt/cm2 intensity over 25 cm2 surface area. Headpiece area of the device was 5 cm2, and the application was performed as the head of device was positioned at 90º (perpendicular) at full contact for 5 minutes by using gel, and performing continuous circular motions.
Study NCT02793401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hotpack
Description: All patients had the same physical therapy (PT) protocol including hot pack (HP) for 20 min/session,
Study NCT02793401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: All patients had the same physical therapy (PT) protocol includingTENS (Fizyotens 4000, Fizyomed Medical Devices Ltd,Turkey) (50-100 Hz) for 20 min/session,
Study NCT02793401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercises
Description: All patients had the same physical therapy (PT) protocol including therapeutic exercises for shoulder muscles
Study NCT02793401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balneotherapy
Description: All patients had the same physical therapy (PT) protocol including balneotherapy in 38-40 °C thermomineralized water for 20 minutes.
Study NCT01879085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: given on days 1 and 8 at 900 mg/m2 IV over 90 minutes (fixed dose infusion rate at 10 mg/m2/min) every 21 days (1 cycle). For dose level -2, given over 67.5 minutes at 10 mg/m2/min
Study NCT01879085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: given orally at the specified dose levels (either 300 mg/daily or 200 mg twice per day) on days -1 to +2 and days +7-9 every 21 days (treatment for 3 days starting one day prior to chemotherapy on every cycle)
Study NCT02952625 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Imaging
Description: Single arm Imaging (PET/MR) study
Study NCT01783639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stent
Description: Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices
Study NCT02610829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gamma tocopherol
Description: 3 doses of 1400 mg gamma tocopherol (2 capsules, each is 700mg), at 12 hour intervals
Study NCT00084318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m\^2 intravenously over 120 minutes on day 1 (week 1) followed by 250 mg/m\^2 intravenously over 60 minutes in weeks 2 through 7.
Study NCT00084318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 30 mg/m\^2 intravenously infused over over 60 minutes in weeks 2 through 7.
Study NCT00084318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 15 mg/m\^2 intravenously infused over 30 minutes in weeks 2 through 7.
Study NCT00084318 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 60 Gy (2 Gy once a day, 5 times a week)
Study NCT03301740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UF profiling during HD
Description: Experimental arm: Linear UF profiling (linearly decreasing UF rate with a UF rate starting at 1.33 times the rate that would be needed at a constant UF rate to achieve the desired post-weight; pre-programmed profile 2 on a Fresenius 2008K machine, the machine used in all participating clinics). Ultrafiltration profiling will be performed using Fresenius 2008K dialysis machines in accordance with manufacturer instructions.
Study NCT03301740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional HD
Description: Control arm: Conventional HD (routine care) is the participant's standard HD prescription without UF profiling.
Study NCT01389570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure wrist band
Description: Use of acupressure wristband during surgery Manufacturer; Pinnacle Ind Ltd, Rm 831 Thriving Ind Ctr, 26-38 Sha Tsui Rd, Tsuen Wan, Hong Kong
Study NCT02999230 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caries Free 1.5% Arginine
Description: Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
Study NCT02999230 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caries Free Placebo Sodium Fluoride
Description: Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
Study NCT02999230 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caries Active 1.5% Arginine
Description: Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
Study NCT02999230 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caries Active- Placebo Sodium Fluoride
Description: Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
Study NCT03508804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Lidocaine Paracervical Block
Description: Paracervical block of 10ml of 1% lidocaine
Study NCT03508804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% Lidocaine Paracervical Block
Description: Paracervical block of 10ml of 1% lidocaine
Study NCT02018237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High fructose corn syrup diet
Description: Subjects will consume a high fructose corn syrup diet for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
Study NCT04220021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is a widely used, well-tolerated drug that has been used for decades as a first-line defense for treating type 2 diabetes. Its safety has been well established. Subjects will begin treatment with Metformin at a dosage of 500mg with an escalation of dosage by 500mg every week to a maximal dosage of 2000mg. Dosing will be twice daily.
Study NCT03200847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with All-Trans Retinoic Acid
Description: All the patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 All-Trans Retinoic Acid orally for 3 days surrounding each of the first four infusions of pembrolizumab
Study NCT03114501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participants receive yoga sessions up to 5 days per week, based on the patient's schedule, over the course of patients' Radiation Therapy (up to 15 sessions, 45-60 min. each). Yoga sessions audio and video recorded.
Study NCT03114501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Questionnaire
Description: Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.
Study NCT03114501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Questionnaires
Description: Symptom questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).
Study NCT01785719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commercial Weight Loss Program
Description: Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA Dietary Guidelines for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
Study NCT03721952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitator-Based Intervention
Description: Facilitators interact in person or by telephone with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email 5 days per week. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
Study NCT03946878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT03946878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT02018237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet (low in high fructose corn syrup)
Description: Subjects will consume a standard diet (low in high fructose corn syrup) for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
Study NCT05174104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation
Description: The home exercise schedule consists of a patient-tailored association of adaptation (without and with the target moving on pitch and yaw planes for 1 min each three times per day), substitution, habituation, and balance and gait exercises. All the unilateral vestibular hypofunction patients will be followed in the clinic twice a week for 4 weeks for 30-45 min and evaluated for adherence. Between supervised sessions, patients will perform a twice-daily home exercise plan for a total of 30-40 min/day
Study NCT01464255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ocufilcon D
Description: Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
Study NCT01464255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ocufilcon B
Description: Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
Study NCT03498326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: One group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2.
Study NCT03498326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2, and receive additional celecoxib 200mg bid every days during chemotherapy period.
Study NCT01405794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 32ppm Silver Particle
Description: Oral silver dose of 32ppm
Study NCT01405794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Water No Silver
Study NCT00953420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m2 IV on Day 1
Study NCT00953420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Target AUC of 5 (mg/ml x min) on Day 1
Study NCT00953420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1
Study NCT05310500 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Finishing files of ProTaper Gold (F2) without effect to NaOCL
Description: Finishing files of ProTaper Gold (F2) without effect to NaOCL
Study NCT05310500 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Finishing files of ProTaper Gold (F2) with effect to NaOCL
Description: Finishing files of ProTaper Gold (F2) with effect to NaOCL
Study NCT01879085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: administered on day 9 subcutaneously at 6 mg
Study NCT02207322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transplant with early palliative care
Description: the intervention include integrating early palliative care with standard transplant care to evaluate and treat patients' symptoms during stem cell transplantation
Study NCT05310500 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
Description: Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
Study NCT05310500 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Finishing files of Dia-X ProTaper (D4) with effect to NaOCL
Description: Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
Study NCT03249246 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT02085616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive service
Description: In the proactive service the callers to the quitline are offered a number of callbacks.
Study NCT02085616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reactive service
Description: In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
Study NCT03768440 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous erector spinae block (ESB)
Description: Erector spinae block: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
Study NCT03768440 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous paravertebral block (PVB)
Description: The paravertebral space (bound medially by the bodies of the vertebrae, intervertebral discs, and intervertebral foraminae; anterolaterally by the parietal pleura and the innermost intercostal membrane; posteriorly by the transverse processes of the thoracic vertebrae, heads of the ribs, and the superior costotransverse ligament) laying between T4/5 is identified using the ultrasound transducer in a transverse orientation; the needle tip is advanced until it is seen passing under the transverse process, immediately superior to the pleura; the pleura is seen to deflect downward with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
Study NCT03768440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)
Study NCT03768440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)
Study NCT03552224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recording of auditory nerve activity
Description: near field recording of auditory nerve activity with contact electrode
Study NCT03530787 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl Zingerone Topical Cream
Description: Topical cream with an active acetyl zingerone component.
Study NCT03530787 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical cream
Description: Topical cream without an active acetyl zingerone component and just the carrier cream.
Study NCT02453217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese CHIP
Description: The CHIP physical health screening tool will be used by community psychiatric nurses in the treatment group to assess patients' physical health risk and identify problematic lifestyle behaviours. The findings from the assessment will be used to devise an individualized care plan with patients. This treatment plan may involve community psychiatric nurses collaborated with psychiatrists, drawing patients attention to indicators of physical health risk by using a traffic light system The community nurses will use motivational interviewing approaches to make patients be aware of their physical health risks and enhance their motivation to adopt healthier behaviours.
Study NCT02453217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: The routine community mental health care provided by the community psychiatric nursing service and outpatient clinic.
Study NCT03150992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elemental 028 Extra Liquid
Description: A nutritionally complete, liquid elemental diet consisting of a mixture of essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and flavourings with sugars \& sweeteners.
Study NCT01875627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Konjac noodles
Description: Replacement of carbohydrate noodles with non-caloric Konjac noodles (viscous gel meal)
Study NCT01875627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Konjac noodles
Description: Replacement of carbohydrate noodles with non-caloric Konjac noodles (viscous gel meal)
Study NCT01875627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate and Konjac Noodles
Study NCT01875627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate and Konjac Noodles
Study NCT01875627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate noodles
Study NCT01875627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate noodles
Study NCT00375050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Study NCT00375050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01335880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coupons for use within the next week
Description: Participants who attend an exercise class will receive a coupon for a free exercise class to be used within the next week.
Study NCT01335880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coupons for use within the next 3 months
Description: Participants who attend an exercise class will receive a coupon to attend an exercise class for free within the next 3 months.